Interview With Axe Pharmaceuticals Owner Dr. Kara Dumitru

Test Volunteers (fp)

The Dead End Daily was able to speak with Dr. Kara Dumitru, owner of Axe Pharmaceuticals, a local company who through no fault of their own have been in the news recently for all the wrong reasons.

Recent headlines detail an outbreak of increased sexual criminality after a batch of Axe Pharmaceuticals pills still in development were stolen. The van they were being transported in was stolen and blown up by the suspected thieves who still remain at large in the Red Light District.

This comes after a theft of Boner Bust sexual aid pills still in development, which also resulted in a steep rise in sexual related crime.

We sat down to speak to Dr Dumitru and she had this to say: “Axe is a pharmaceutical research company that tries to stay on the cutting edge of developments. We supply the local hospital and a few outlying emergency centers with their narcotics, as well as aid in research and development. the latest trial was called unofficially Boner Boost. It was meant to replace Viagra and it also affected women as well as men.”

“During the trial for the pill known as Boner Boost, there were some side effects that were reported back and the product was recalled immediately. Unfortunately, the truck containing the recalled batch of Boner Boost was stolen and destroyed the other day. Anyone suffering from the drug itself can be treated at the local hospital, I’m sure. It is not a long-lasting drug though, so I don’t foresee anything else major going on with it. My team will work to refine the pill so the effects are more desirable and controlled. For now, I’ll be having my staff working with local law enforcement to investigate any cases related.”

On the theory that the crime was premeditated or industrial espionage to discredit Axe Pharmaceuticals, Dr Dumitru said, “I am going to assume that if there was anything premeditated or any cases as a result of the drug, I would have been notified. so, officially, on the record, Axe is recalling a product that failed the trial and is offering to pay for treatment needed though it is not a long-lasting drug.”